Atypical Amiodarone toxicity: Iatrogenic ataxia and dysarthria in an elderly female

Amanda Warren; Dana Lin; Ashlyn Katz; Pola Boazak

doi:10.5430/crim.v7n4p13

Case Reports in Internal Medicine ›› 2020, Vol. 7 ›› Issue (4) :13 -14. DOI: 10.5430/crim.v7n4p13

CASE REPORTS

research-article

Atypical Amiodarone toxicity: Iatrogenic ataxia and dysarthria in an elderly female

Amanda Warren ¹^,²^,^*
, Dana Lin ¹^,²
, Ashlyn Katz ¹^,²
, Pola Boazak ¹^,²

Author information +

History +

PDF (360KB)

Abstract

Amiodarone is one of the most frequently used antiarrhythmic drugs on the market, treating both life-threatening ventricular arrhythmias as well as supraventricular tachyarrhythmias. Some of its most commonly known side effects include corneal deposits, cardiac toxicity, pneumonitis, thyroid hormone fluctuation, and dermatological reactions. Despite the frequency of occurrence of neurological complications secondary to Amiodarone they remain to be under-recognized by healthcare professionals. This case report aims to increase awareness of the neurological complications of Amiodarone.

Keywords

Amiodarone toxicity / Cerebellar ataxia / Neurological side effects

Cite this article

Download citation ▾

Amanda Warren, Dana Lin, Ashlyn Katz, Pola Boazak. Atypical Amiodarone toxicity: Iatrogenic ataxia and dysarthria in an elderly female. Case Reports in Internal Medicine, 2020, 7(4): 13-14 DOI:10.5430/crim.v7n4p13

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Hindle JV, Ibrahim A, Ramaraj R. Ataxia caused by amiodarone in older people. Age Ageing. 2008 May; 37(3): 347-8. PMid:18385185. https://doi.org/10.1093/ageing/afn063

[2]	Sloskey GE. Amiodarone: a unique antiarrhythmic agent. Clin Pharm. 1983; 2(4): 330-340.

[3]	Kodama I, Kamiya K, Toyama J. cellular electropharmacology of amiodarone. Cardiovascular research. 1997; 35(1): 13-29. https://doi.org/10.1016/S0008-6363(97)00114-4

[4]	Hindle JV, Amin I, Radhakrishnan R. Ataxia caused by amiodarone in older people. Age and Ageing. 2008; 37(3): 347-348. PMid:18385185. https://doi.org/10.1093/ageing/afn063

[5]	Ernst AR, Philip JP, Bernard L. Side effects and complications of amiodarone therapy. American Heart Journal. 1985; 109(5): 975-983. https://doi.org/10.1016/0002-8703(85)90238-8

[6]	Aronson JK. Meyler’s Side-Effects of Drugs. 2006. 15th edition. Elsevier pg.154.

[7]	Gurkov R. Amiodarone: a newly discovered association with bilateral Vestibulopathy. Front Neurol. 2018; 9: 119. PMid:29559948. https://doi.org/10.3389/fneur.2018.00119

[8]	Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009; 66(7): 865-9. PMid:19597088. https://doi.org/10.1001/archneurol.2009.96

[9]	Park HS, Kim YN. Adverse effects of long-term amiodarone therapy. Korean J Intern Med. 2014; 29(5): 571-573. PMid:25228830. https://doi.org/10.3904/kjim.2014.29.5.571

[10]	Danielle G, Angela CL. Dronedarone: A New Antiarrhythmic Agent for the Treatment of Atrial Fibrillation. Cardiology in Review. 2009; 17(5): 230-234. PMid:19690474. https://doi.org/10.1097/CRD.0b013e3181b15ab9

[11]	Somani P. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies. J Clin Pharmacol. 1989 May; 29(5): 405-12. PMid:2544634. https://doi.org/10.1002/j.1552-4604.1989.tb03352.x